B J Hoogwerf

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Blood glucose concentrations < or = 125 mg/dl and coronary heart disease risk
    Byron J Hoogwerf
    Preventive Cardiology and Rehabilitation Department, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:596-9. 2002
  2. ncbi Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, OH 44195, USA
    Cleve Clin J Med 75:729-37. 2008
  3. ncbi Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 73:477-84. 2006
  4. ncbi Postoperative management of the diabetic patient
    B J Hoogwerf
    Department of Endocrinology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Med Clin North Am 85:1213-28. 2001
  5. ncbi Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, USA
    Vasc Health Risk Manag 4:355-62. 2008
  6. ncbi The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not
    B J Hoogwerf
    Department of Endocrinology, Cleveland Clinic, OH 44195, USA
    Cleve Clin J Med 67:287-93. 2000
  7. ncbi Perioperative management of diabetes mellitus: how should we act on the limited evidence?
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cleve Clin J Med 73:S95-9. 2006
  8. ncbi Diabetes mellitus--overview
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Foot Ankle Clin 11:703-15. 2006
  9. ncbi Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial
    B J Hoogwerf
    Cleveland Clinic Foundation, OH 44195, USA
    Diabetes 48:1289-94. 1999
  10. ncbi All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study
    K B Doshi
    Department of Endocrinology, Diabetes and Metabolism, The Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA
    Diabetes Obes Metab 11:102-8. 2009

Detail Information

Publications44

  1. ncbi Blood glucose concentrations < or = 125 mg/dl and coronary heart disease risk
    Byron J Hoogwerf
    Preventive Cardiology and Rehabilitation Department, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:596-9. 2002
  2. ncbi Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, OH 44195, USA
    Cleve Clin J Med 75:729-37. 2008
    ....
  3. ncbi Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 73:477-84. 2006
    ..Glucagon-like peptide 1 (GLP-1), produced in the small intestine, and amylin, produced by beta cells in the pancreas, also have glucose-lowering effects. Synthetic analogues of these hormones are now available for clinical use...
  4. ncbi Postoperative management of the diabetic patient
    B J Hoogwerf
    Department of Endocrinology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Med Clin North Am 85:1213-28. 2001
    ....
  5. ncbi Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, USA
    Vasc Health Risk Manag 4:355-62. 2008
    ..These data indicate that pramlintide has a role in glycemic control of both type 1 and type 2 DM. Pramlintide use is associated with favorable effects on weight, lipids and other biomarkers for atherosclerotic disease...
  6. ncbi The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not
    B J Hoogwerf
    Department of Endocrinology, Cleveland Clinic, OH 44195, USA
    Cleve Clin J Med 67:287-93. 2000
    ..On the other hand, vitamin E in the doses and duration studied (400 IU/day for 4.5 years) did not lower risk significantly...
  7. ncbi Perioperative management of diabetes mellitus: how should we act on the limited evidence?
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cleve Clin J Med 73:S95-9. 2006
    ..There is little role for oral antidiabetic medications in the early postoperative phase...
  8. ncbi Diabetes mellitus--overview
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Foot Ankle Clin 11:703-15. 2006
    ..Additional management strategies include laser therapy for retinopathy and appropriate footwear to reduce the risk of lower extremity amputations...
  9. ncbi Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial
    B J Hoogwerf
    Cleveland Clinic Foundation, OH 44195, USA
    Diabetes 48:1289-94. 1999
    ..The small number of diabetic patients provided limited power to detect significant differences between diabetic and nondiabetic patients or between diabetic patients in the aggressive versus moderate cholesterol treatment strategies...
  10. ncbi All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study
    K B Doshi
    Department of Endocrinology, Diabetes and Metabolism, The Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA
    Diabetes Obes Metab 11:102-8. 2009
    ..We analysed which component(s) of NCEP MS criteria had greatest predictive value for mortality...
  11. ncbi Preoperative triglycerides predict post-coronary artery bypass graft survival in diabetic patients: a sex analysis
    D L Sprecher
    Department of Preventive Cardiology and Rehabilitation, Cleveland Clinic Foundation, Ohio 44195, USA
    Diabetes Care 23:1648-53. 2000
    ..This study evaluates the predictive value of serum triglyceride levels on mortality in post-coronary artery bypass graft (CABG) diabetic patients with subsequent analysis by sex...
  12. ncbi Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
    ..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
  13. ncbi Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease
    Mehdi H Shishehbor
    Department of Internal Medicine, Cardiovascular Imaging Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 91:1514-7, A9. 2003
  14. ncbi Clinical utility of waist circumference in predicting all-cause mortality in a preventive cardiology clinic population: a PreCIS Database Study
    Harpreet S Bajaj
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, Ohio, USA
    Obesity (Silver Spring) 17:1615-20. 2009
    ....
  15. ncbi The relationship of glycaemic control and triglycerides in patients with diabetes mellitus: a PreCIS Database Study
    M B Davidson
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH 44195, USA
    Diabetes Obes Metab 11:118-22. 2009
    ....
  16. ncbi Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure
    W H Wilson Tang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 41:1394-8. 2003
    ..We sought to define the characteristics of fluid retention after thiazolidinedione (TZD) initiation in patients with established heart failure (HF)...
  17. ncbi Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 101:1741-6. 2008
    ..5 micromol/L (the top tertile) were associated with a sevenfold greater mortality risk. In conclusion, homocysteine and fibrinogen levels explain nearly 40% of the attributable mortality risk from CKD...
  18. ncbi High school body mass index and body mass index at entry to a cardiac disease risk prevention clinic and the association to all-cause mortality and coronary heart disease: a PreCIS database study
    Katherine K Gambino
    Preventive Cardiology and Rehabilitation and Nurse Manager, Women s Cardiovascular Center, Cleveland Clinic, Ohio, USA
    J Cardiovasc Nurs 25:99-105. 2010
    ....
  19. ncbi Cholesterol guidelines update: more aggressive therapy for higher-risk patients
    Julie C Huang
    Preventive Cardiology Section, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 72:253-62. 2005
    ..These more aggressive guidelines are based on results of five clinical studies published since 2001...
  20. ncbi Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study
    A G Ioachimescu
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH 44195, USA
    Diabet Med 24:1369-74. 2007
    ..To determine the association of serum uric acid with all-cause mortality and hyperglycaemia in patients with Type 2 diabetes...
  21. ncbi Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study
    Adriana G Ioachimescu
    Cleveland Clinic, Cleveland, Ohio 44195, USA
    Arthritis Rheum 58:623-30. 2008
    ..The purpose of this study was to evaluate the prognostic value of serum uric acid levels in a large cohort of men and women at high risk of cardiovascular disease...
  22. ncbi A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia
    Vijay Nambi
    Department of Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 69:985-9. 2002
    ..Thiazolidinedione drugs increase insulin sensitivity, but their use in the metabolic syndrome is only speculative at present. We recommend they be used only as indicated to treat diabetes mellitus...
  23. ncbi Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprotein cholesterol ratio in patients without diabetes mellitus
    Michael B Davidson
    Department of General Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:123-6. 2005
    ..3, 95% confidence interval 2.6 to 16.4, p <0.0001) before the development of abnormal levels of fasting blood glucose...
  24. ncbi Relation of albumin/creatinine ratio to C-reactive protein and to the metabolic syndrome
    Adrian W Messerli
    Department of Preventive Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 92:610-2. 2003
    ..These data demonstrate that CRP independently predicts the presence of UAE, a marker of endothelial dysfunction...
  25. ncbi Advances in the treatment of diabetes mellitus in the elderly. Development of insulin analogues
    B J Hoogwerf
    Department of Endocrinology, Cleveland Clinic Foundation, Ohio, USA
    Drugs Aging 9:438-48. 1996
    ....
  26. ncbi Autoantibodies to IA-2 and GAD65 in patients with type 2 diabetes mellitus of varied duration: prevalence and correlation with clinical features
    Y Z Grasso
    Department of Clinical Pathology, L30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Endocr Pract 7:339-45. 2001
    ..166; P = 0.48). CONCLUSION: Irrespective of duration of disease, measurement of IA-2Ab and GADAb can help to identify those patients with type 2 diabetes most likely to require insulin therapy...
  27. ncbi Association of dyslipidemia and effects of statins on nonmacrovascular diseases
    Sarkis B Baghdasarian
    Cardiovascular Medicine Department, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Ther 26:337-51. 2004
    ..Statins have mechanisms of action that expand their effects beyond cholesterol lowering and atherosclerotic medical conditions...
  28. ncbi Reversible decerebrate posturing after profound and prolonged hypoglycemia
    M M Kirk
    Department of Pulmonary Disease, Cleveland Clinic Foundation, Ohio
    Cleve Clin J Med 58:361-3. 1991
    ..We present the case of a patient who recovered fully from prolonged decerebrate rigidity associated with hypoglycemic coma. This case emphasizes the possibility of recovery from severe, prolonged hypoglycemia...
  29. ncbi A summary of the findings from the Post-CABG trial
    B J Hoogwerf
    Cleveland Clinic Foundation, University of Minnesota, Cleveland, USA
    Minerva Cardioangiol 50:291-9. 2002
    ..At the time of the extended follow-up the aggressive lipid strategy was associated with reduced clinical events; low dose warfarin was also associated with reduced clinical events...
  30. ncbi Pancreas transplantation in type 1 diabetes: hope vs reality
    J T Mayes
    Department of General Surgery, Cleveland Clinic, OH 44195, USA
    Cleve Clin J Med 67:281-6. 2000
    ..Increasing evidence suggests that it may slow the progression of long-term diabetic complications. On the other hand, patients risk the adverse effects of lifelong immunosuppression...
  31. ncbi Renin-angiotensin system blockade and cardiovascular and renal protection
    Byron J Hoogwerf
    Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 105:30A-5A. 2010
    ..However, telmisartan showed better tolerability than ramipril in ONTARGET, with less cough and angioedema. This difference was obtained despite patients having been selected for tolerability to both drugs at study entry...
  32. ncbi Association of triglyceride-to-HDL cholesterol ratio with heart rate recovery
    Mehdi H Shishehbor
    Department of Internal Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Diabetes Care 27:936-41. 2004
    ..49, 95% CI 1.08-2.04; P = 0.015). CONCLUSIONS: HRR is associated with triglyceride-to-HDL cholesterol ratio and identifies patients with insulin resistance who are at increased risk of death...
  33. ncbi Elevated international normalized ratio in the ED: clinical course and physician adherence to the published recommendations
    Ashish Atreja
    Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Emerg Med 23:40-4. 2005
    ..There is a need for formal endorsement of recommendations by emergency medicine organizations and development of disposition criteria based on bleeding status and site of bleeding...
  34. ncbi Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study
    Johannes F E Mann
    Department of Cardiology and Population Health Research Institute, McMaster University, Hamilton, Canada
    J Am Soc Nephrol 14:641-7. 2003
    ..Microalbuminuria itself predicts clinical proteinuria in nondiabetic and in diabetic people. Ramipril prevents or delays the progression of albuminuria...
  35. ncbi Heart rate and blood pressure responses to mental stress and clinical cardiovascular events in men and women after coronary artery bypass grafting: the Post Coronary Artery Bypass Graft (Post-CABG) biobehavioral study
    J Alan Herd
    Department of Medicine, Baylor College of Medicine, Houston, Tex, USA
    Am Heart J 146:273-9. 2003
    ..01; SBP, P =.07; DBP, P =.01). CONCLUSIONS: Vigorous HR and BP responses to MST may be markers for a lower risk of incidence of clinical cardiovascular events among patients who have undergone recent CABG surgery...
  36. ncbi Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study
    Johannes F E Mann
    Department of Cardiology, McMaster University, Hamilton, Canada
    Am J Kidney Dis 42:936-42. 2003
    ..We studied changes in serum creatinine levels during 3.5 to 5.5 years in a large cohort of people with diabetes at high cardiovascular risk with microalbuminuria or normalbuminuria...
  37. ncbi The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial
    Bernard Zinman
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada
    Ann Intern Med 146:477-85. 2007
    ..Exenatide therapy is effective in combination with metformin or sulfonylureas for treating type 2 diabetes. Thiazolidinediones (TZDs) also are commonly used, but the efficacy of exenatide with a TZD has not been reported...
  38. ncbi HgbA1c and glucose control: we cannot play it straight with patients
    Byron J Hoogwerf
    J Lab Clin Med 147:5-6. 2006
  39. ncbi Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study
    Johannes F E Mann
    Department of Nephrology and Hypertension, Schwabing General Hospital, Munich, Germany
    Kidney Int 65:1375-80. 2004
    ..There are no data for renal insufficiency before the stage of terminal renal failure. We evaluated effects of vitamin E supplementation on cardiovascular and renal outcomes in 993 people with a serum creatinine > or =1.4 to 2.3 mg/dL...
  40. ncbi Nutrition recommendations and interventions for diabetes--2006: a position statement of the American Diabetes Association
    John P Bantle
    Diabetes Care 29:2140-57. 2006
  41. ncbi Coronary artery bypass graft surgery and cognitive performance
    Gilles Dupuis
    Department of Psychosomatic Medicine, Montreal Heart Institute, Montreal, Quebec, Canada
    Am J Crit Care 15:471-8; quiz 479. 2006
    ..Some studies have indicated a decline in patients' cognitive performance after coronary artery bypass graft surgery...
  42. ncbi Quality of life after coronary artery bypass graft: results from the POST CABG Trial
    Norma Lynn Fox
    Maryland Medical Research Institute, Baltimore, MD, USA
    Chest 126:487-95. 2004
    ..Low-dose anticoagulation therapy did not reduce the progression of atherosclerosis. We conducted this analysis to determine the effects of both lipid-lowering and low-dose anticoagulation therapy on health-related quality of life (HRQL)...
  43. ncbi A DASH-like diet can decrease cardiovascular risk, but barriers to implementation exist
    Byron J Hoogwerf
    Cleve Clin J Med 71:755-6. 2004
  44. ncbi Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association
    John P Bantle
    Diabetes Care 31:S61-78. 2008